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Introduction
Pseudohypoparathyroidism (PHPT) is an unusual disease,
which is characterized by the resistance of bones and kidney to
PTH, followed by hypocalcaemia, hyperphosphataemia, glan-
dular hypertrophy and hypersecretion of PTH. Patients with
PHPT clinically manifest tetany seizures, soft tissue calcifica-
tions and many congenital malformations. Clinical symptoms
may be different and depend on genetic defect or its selectivity
with reference to the tissues. 
At present we can distinguish three types of PHPT and pseu-
do-PHPT. The disease usually appears in the infancy. Early di-
agnosis and vitamin D3 or calcium treatment seem to be the
most important for patient's condition. Too late treatment
threatens with brain calcification followed by neurological de-
fects and mental retardation. 
In this paper we discuss two different patients (A.S., 32 years
old male patient with PHPT type 1b, and L.M., 66 years old fe-
male patient with 1a PHPT) that during the treatment of
hypocalcemia developed hypercalcitoninemia.
Subjects and methods
Our institutional ethics committee approved this study and writ-
ten informed consent was obtained from the subjects. The clini-
cal study was performed in accordance with the principles of
the Helsinki Declaration.
Patients
A.S.
A 32-year-old Italian man was referred to “Azienda Ospedaliera
Careggi” hospital (Florence) in 1986 because of recent com-
plain of severe asthenia, dating back at least 5-6 years, and
paresthesias of the legs. His father was affected by Alzheimer
disease since many years; he had five brothers which were in
apparently good health. In the past, he had presented signs
and symptoms of tetany during severe febrile episodes, char-
acterized by muscle twitches, cramps and carpopedal spasms.
He had no ever smoked. Moreover, he had arterial hypotension
(105/80) with 70 b/min; his height was 173 cm, and his weight
was 68 kg. There were no somatic phenotypic abnormalities
but Chvostek and Trousseau signs (after 25-30 sec) at the first
visit were clearly positive. Electromyography (EMG) and elec-
troencephalogram (EEG) confirmed hypocalcemic signs; in-
tracranial calcifications of the basal ganglions were detected
when computed tomography (CT) was performed.
Serum total calcium varied from 1,51-1,61 mmol/L, albumin 37-
44 g/L, phosphate 1,51-1,69 mmol/L and ionized calcium 0,52 -
0,55 mmol/L. Serum intact PTH levels were 153 and 155 ng/L
(normal range: 10-65) and 25(OH)D3 was 40 nmol/L (normal
range: 2.25-107.5); serum 1-25(OH)2D3 was 51,60 pmol/L
(normal range: 36-144). Serum and urine magnesium and cre-
atinine clearance were normal. Twenty-four-hour urine calcium
was 28 mg. Bone formation and resorption markers were nor-
mal. Bone mineral densities measured by dual-energy X-ray
absorptiometry (DEXA) were within normal limits at the lumbar
spine. Intravenous infusion of 200 units of synthetic 1-34 PTH
( P a r a t h a r®) over 10 minutes was associated with a failure to
significantly rise urinary cyclic AMP (from 1,50 mmol/mg creati-
nine to 4,09 mmol/mg creatinine) and phosphate in urine (that
increased only from 112.69 to 243.46 mmol/g creatinine) (Tab.
I) in comparison with normal subjects and with hormonopenic
hypoparathyroidism patients. 
A series of standard provocative test were performed in this pa-
tient. TRH test (for TSH, GH and prolactin-PRL) (Tab. II), GNRH
test (for LH, FSH, PRL) (Tab. III), AVP infusion test (for serum
osmolality) (Tab. IV), glucagon test (for plasma glucose, Insulin,
serum Insulin C peptide, GH and cortisol) (Tab. V) were normal.
Basal serum calcitonin was in the normal range but after calci-
um and calcitriol supplementation significantly increased, dur-
ing years 1986-2003 (Tab. VI). Thyroid ultrasound examination
was always considered normal; no nodules were seen. Calci-
tonin values of relatives were in the normal range. Serum CEA
was always in the normal range. Genetic analysis of GNAS1
gene showed an heterozygous T>C variant at the nucleotide
position 433-18 (intron 5). 
L.M.
A 66-year-old Italian lady was referred to “Azienda Ospedaliera
Careggi” Hospital (Florence) in 1999 because of severe
hypocalcemia (1,25 mmol/L) and marked increase of plasma
PTH (772 ng/L) detected during an evaluation for unexplained
seizures. Serum magnesium levels were in the normal range.
CT scan detected intracranial severe basal ganglion calcifica-
tions. She was born in a very small town near Napoli (Southern
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Table I - 1-34 PTH intravenous infusion test (200 UI) over 10 minutes.The peak response in normal subjects is 50- to 100-fold times basal;
patient shows only a 2-fold increase.
B1 B2 0-30 min 30-60 min 60-120 min
P (ur) 104.29 112.69 243.46 238.95 129.16 mmol/g creat
Nephrogenous cAMP 1.84 1.5 2.34 2.61 4.09 nmol/mg creat
Table II - TRH test (iv injection of 200 mg) (1987).
Basal 15 min 30’ min 60 min 120 min
GH (ng/mL) 1.2 0.5 0.4 0.8 0.5
TSH (mU/L) 4.64 26.69 26.31 18.40 9.72
PRL (mU/L) 2.5 8.2 8.0 4.1 12.1
Table III - GNRH test (iv injection of 100 mg) (1987).
Basal 15 min 30 min 60 min 120 min
FSH (mU/L) 5.0 5.6 5.9 6.8 6.5
LH (mU/L) 14.9 62.5 61.0 45.7 30.3
PRL (mU/L) 3.9 3.5 2.5 1.9 1.5
Table IV - AVP test (im injection of 4 mg).
Basal 3 h 5 h 15 h
Plasma osmolality (mOsm/L) 279 276 275 274
Table V - Glucagon test (iv injection of 500 mg) (1991).
0 30’ 60’ 90’ 120’ 150’ 180’ 210’ 240’
Glucose (mg/dL) 77 131 83 71 60 71 79 78 78
Insulin (mU/L) 15.3 57.9 10.6 5.5 4.0 3.6 4.0 4.5 4.1
C-peptide (pg/mL) 10.6 37.0 2.7 1.1 0.7 0.7 0.7 0.7 1.1
GH (ng/mL) 10.73 0.08 0.23 0.77 9.70 10.2 3.57 0.89 0.47
Cortisolo (nmol/L) 369.0 255 329 260 653 863 1012 982 815
Table VI - Calcitonin values during years of patient A.S.
1986 1992 1997 1998 2001 2003
Calcium (mmol/L) 1.53 2.10 2.21 2.00 1.95 2.18
PTH (nmol/L) 18.3 14.5 21.6 22.1 14.6 18.2
Calcitonin (2-10 pg/mL) 11.3 10.5 8.99 16.7 51.9 15.4
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Italy). She was the second of 8 relatives (5 sons, 3 daughters,
Fig. 1); the relatives II-6 (male) and II-7 showed intracranial
ganglion calcifications but they refused any other examination.
Her menses were regular until the age of 52 years, but she had
no pregnancy. She was operated on for bilateral eye cataract.
Her heigth was 145 cm and her weight was 55 kg; she exhibit-
ed also a round face, with minimal mental retardation. No signs
of brachydactyly neither of heterotopic calcifications were pre-
sent at the clinical and radiological examinations. From many
years she suffered by diffuse unexplained paresthesias. 
Creatinine clearance, as well as 25(OH)D3 was 54,66 nmol/L
(2.25-107.5); serum 1-25(OH)2D3 was 58,32 pmol/L (36-144)
were normal. Bone mineral densities measured by dual-energy
X-ray absorptiometry (DEXA) were lower than the normal limits
at the lumbar spine (BMD: 0,758; T: –2,92). She manifested al-
so a severe olfactory impairment, confirmed by olfactive
evoked potentials test; no gustatory neither auditory abnormali-
ties were found. Organ and non-organ specific antibodies were
studied, but only anti-parietal cells of gastric mucosa antibodies
were found positive; basal gastrin serum level was very high
(356 pg/mL). Calcitonin serum basal levels were high (17,7
pg/mL). No other endocrine abnormality was found. 
Patient started a therapy with calcium (500 mg t.i.d. and cal-
citriol 0,5 mg o.i.d.). Calcitonin significantly raised during the
years (Tab. VII). Ultrasound examination of thyroid gland re-
vealed a multinodular euthyroid goitre (prevailing in the right
lobe); suspecting the presence of medullary thyroid carcino-
ma, a pentagastrin test was performed, that showed a marked
rise of stimulated calcitonin (Tab. VIII). For this reason L.M.
was operated on (total thyroidectomy); histopathology of ex-
cised thyroid gland showed diffuse hyperplasia (not nodular)
of C-cells in colloid goitre and immunohistochemistry examina-
tion detected positive reaction for calcitonin, cromogranin and
CEA. During surgery no hypertrophic parathyroid glands were
found. 
After the surgical intervention, patient was substituted with l-
thyroxine (100 mg/die); calcitonin rapidly decreased to very low
serum levels (Tab. VII). The diffuse paresthesias decreased in
few days and at the end of the first month after surgery com-
pletely stopped; olfactory impairment remained. No mutation of
GNAS1 gene were observed in this patient.
Hormone assays
All the hormonal determinations (fT3, fT4, TSH, Insulin, c-Pep-
tide, LH, FSH, GH, prolactin, c-AMP, cortisol, PTH) were per-
formed by standard laboratory methods (radioimmunometric or
immunochemiluminometric or immunoenzymometric assays,
as appropriate) in the Hormonal Section of the General Labora-
tory of Azienda Ospedaliera di Careggi and in the Nuclear
Medicine Laboratory Unit of the University of Firenze. Serum
calcitonin was evaluated by a two-site immunoradiometric as-
say using ELISA-hCT kit (CIS, Gif-sur-Yvette, France); normal
basal levels were 2-10 pg/mL. 
Genetic analysis of the GNAS1 gene
Genomic DNA was isolated from peripheral EDTA blood sam-
ples of the hypocalcemic and healthy population with the phe-
nol/chloroform procedure. Exons 1-13 of the Gsa e n c o d i n g
gene (GNAS1) were amplified in 50 mL by PCR reaction con-
taining 67 mM Tris-HCl, 16.6 mM (NH4)2S O4, 5 mM MgCl2,
0.01% Tween-20, 200 m M each of the four deoxyribonu-
cleotides, 0.4 mM of oligonucloetide primers and 1U of Polytaq
(Polymed, Florence, Italy) (1). The length of the PCR products
wa  analyzed on 3% agarose gels, stained with ethidium bro-
mide and visualized with UV light. In each subject both strands
of each exon were sequenced. Sequencing of the PCR prod-
ucts using both sense and antisense primers was performed
using AmpliTaq BigDye Terminator kit and 3,100 Genetic Ana-
lyzer (Applied Biosystems).
Discussion
Pseudohypoparathyroidism is a rare disorder characterized by
increased levels of PTH in spite of severe hypocalcemia and
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Figure 1 - Genealogic tree of L.M. kindred; filled circles indicate patients
with Fahr syndrome (basal ganglion calcifications).
Table VII - Calcitonin values during years of patient L.M.
1999 Jan 2000 May 2000 Nov 2000 Jun 2001*
Calcium (mmol/L) 1.25 2.08 2.28 2.37 2.26
PTH (ng/L) 772 526 430 240 291
Calcitonin (2-10 pg/mL) 17.7 29 54 82.3 2.2
* After total thyroidectomy.
Table VIII - Pentagastrin test (iv bolus injection of 0,1 m g/kg). CEA was 3,1 ng/mL, gastrin was 308 pg/mL (<108), calcium was 2,13 mmol/L.
-15 min 0 1 min 2 min 3,5 min 5 min 7 min
Calcitonin (pg/mL) 64 69 160 192 151 148 128
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hyperphosphatemia. Several forms of PHPT have been de-
scribed: PHPT type 1a (typical Albright hereditary osteodystro-
phy [AHO], absent response to PTH infusion, generalized hor-
mone resistance, reduced Gsa activity); pseudo-PHPT (typical
AHO, normal serum calcium levels); PHPT type 1b (normal
phenotype, defective response to PTH infusion, low serum cal-
cium, normal Gsa activity); PHPT type 1c (typical AHO, defec-
tive response to PTH infusion, generalized hormone resis-
tance, normal Gsa activity); PHPT type 2 (low serum calcium,
normal cAMP response to PTH infusion, defective urine phos-
phorus response to PTH infusion). 
Very few data exist about C-cells dysfunction in patients with
PHPT; moreover, both normal calcitonin (CT) levels (2-4) and
increased CT levels (5-7) have been reported. Calcitonin is a
32 amino acid hormone secreted by thyroid C-cells; its receptor
is a member of the family of G protein-coupled receptors (8).
Usually hypercalcitoninemia is due to medullary thyroid carci-
noma, and to several other conditions, such as hypergastrine-
mia, chronic lymphocytic thyroiditis and renal failure. The re-
cent prospective study of C-cell function in patients with PHPT
(9) seems to have demonstrated that high levels of serum cal-
citonin may be found only in patients with PHPT 1a; it may be
associated to resistance to calcitonin, as suggested by the usu-
al impairment of G-protein transduction in patients with PHPT
1a (10) and confirmed by the normal plasma calcitonin levels in
patient with PHPT 1b, in which resistance is typically restricted
to PTH only (11).
We studied two patients with PHPT, A.S. with type 1b and L.M.
with type 1a. In contrast with Vlaeminck-Guillem data (9) we
observed high calcitonin serum levels also in the patient with
PHPT 1b. No good explanation for the high calcitonin basal
level and secretion was found for the patient with PHPT 1b. We
were unable to demonstrate, during many years of follow-up,
any cause of hypercalcitoninemia: no renal impairment, lym-
phocytic chronic thyroiditis, hypergastrinemia or medullary thy-
roid carcinoma were found. However we have to consider that
patient’s calcitonin serum levels increased after calcium sup-
plementation. Calcium is one of the usual provocative stimulus
agent used worldwide to induce calcitonin response. The
mechanism underlying calcium-evoked calcitonin release is not
fully understood, depending on also by the rate of increase in
plasma Ca2+ (12). Calcium can operate directly on parafollicu-
lar cells or indirectly on gastrin-cells, inducing an increased re-
lease of gastrin and secondarily calcitonin increase. Calcium-
sensing receptor is expressed in human gastrinoma cells and
could be involved in the mechanism of calcium-evoked gastrin
release (13). So we may hypothesize that chronic calcium ad-
ministration is the mechanism by which our patient with PHPT
Ib developed hypercalcitoninemia. 
In the patient with PHPT 1a we observed high plasma levels of
calcitonin since the first examination. C-cells function in this
subject may be deranged by several different causes and
mechanisms. She had basal hypergastrinemia due to atrophic
autoimmune gastritis; hypergastrinemia is one of the known
conditions able to induce hypercalcitoninemia (14). Moreover
chronic calcium administration to normalize calcium serum lev-
els could directly stimulate calcitonin serum levels. So, in this
particular patient, three different mechanism seems to take part
in hypercalcitoninemia: resistance to calcitonin, hypergastrine-
mia for atrophic gastritis, calcium administration. However C-
cells appear to respond adequately to the stimulating penta-
gastrin infusion inducing a marked rising in calcitonin, confirm-
ing the normality of C-cell function. An abnormal pentagastrin
response is known to be a specific marker for medullary thyroid
carcinoma, but in our PHPT 1a patient pathological examina-
tion failed to show any evidence of tumor in the excised gland,
in agreement with the literature data (5, 15, 16), finding only C-
cell hyperplasia. 
C-cell hyperplasia precedes the development of medullary thy-
id carcinoma in multiple endocrine neoplasia type 2A
(MEN2A). Identification of abnormal calcitonin levels after a
provocative stimulus is a technique that has been widely used
to diagnose this preneoplastic condition in an early stage dur-
ing the development of medullary thyroid carcinoma, when total
thyroidectomy is likely to be curative. C-cell hyperplasia due to
ome mechanism other than the presence of the PHPT gene
mutation may also happen in PHPT 1a kindreds. We cannot
exclude the likelihood of developing a medullary thyroid carci-
noma in our patient, for the several different mechanism con-
tributing to hypercalcitoninemia. At last the molecular basis of
the severe olfactory abnormality, without any other abnormali-
ties regarding gustatory and auditory pathways, is obscure
c nsidering the unique G proteins that regulate signal trans-
duction pathways related to vision, olfaction and taste (17-20).
In conclusion, hypercalcitoninemia may be mostly correlated to
calcium therapy in PHPT 1b subjects rather than the presence
of the genetic abnormality. On the contrary, hypercalcitonine-
mia seems to be a new described feature of patient with PHPT
1a, of which you to take in account when other different factors
for rising calcitonin levels are present, for the risk to develop
medullary tumors of the thyroid.
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